Ubie, a Tokyo-based startup providing an AI-powered symptom checker app and hospital SaaS products, has closed a $19 million extension to its previous Series C round. This brings the health tech startup’s total funding to $45.2 million in Series C.
The extension round consists of 90% equity and 10% debt financing, according to the co-founder and CEO of Ubie Kota Kubo. With this round, Ubie has raised a total of $76 million since its inception in 2017.
The startup declined to comment on its company valuation, but a source familiar with the situation, who wished to remain anonymous, told TechCrunch its valuation is now estimated at $250 million. Investors in the latest funding include Sogo Medical, AAIC Investment, Japan Impact Investment, Rakuten Capital, Shoko Chukin Bank, Japan Finance Corporation and Mizuho Bank.
Ubie isn’t the only health tech company developing an AI-enabled symptom checker for users. A Boston-based startup, Buoy Health, built a symptom check app using AI; Berline-based Ada Health also developed an AI-driven symptom assessment app; and IBM’s Mediktor helps people with symptom assessment. Kubo pointed out, as a differentiator, that Ubie offers a B2B product called Ubie for Hospital, also known as AI Monshin, and a B2C app for individual users.
The Ubie for hospitals, allowing doctors to reduce their time for taking notes of patients’ histories, is a medical questionnaire software for patients to have a preliminary interview via a tablet while waiting before meeting doctors.